A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Open Access
Abstract
Insomnia affects 4.4–4.8% of the world’s population, but because the effect of hypnotic drugs is limited and may cause harmful side-effects, scientists are turning their attention to developing drugs that act on the orexin system. Daridorexant, a selective dual-orexin receptor antagonist (DORA), has exhibited promising results in both animal and human studies. Its activity was evaluated based on the physiology-based pharmacodynamic and pharmacokinetic model. The use of daridorexant is considered safe, with no clinically significant side-effects including deprivation of next-morning residual effects. In this manuscript we conducted a comprehensive review of daridorexant including pharmacodynamics, animal and human research, pharmacokinetics and safety.Keywords
Funding Information
- Statutory Funds of the Medical University of Lublin, Poland (DS 23/22 Grazyna Biala)
This publication has 27 references indexed in Scilit:
- Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia DisorderAnnals of Neurology, 2020
- Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administrationEuropean Neuropsychopharmacology, 2019
- Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass SpectrometryCurrent Drug Metabolism, 2019
- Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human StudyClinical Pharmacology & Therapeutics, 2018
- The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468The Journal of Pharmacology and Experimental Therapeutics, 2017
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice GuidelineJournal of Clinical Sleep Medicine, 2017
- Prevalence of self-reported insomnia in general population of PolandPsychiatria Polska, 2016
- The Pathophysiology of InsomniaChest, 2015
- Drugs for insomniaExpert Opinion on Emerging Drugs, 2012
- Epidemiology of insomnia: what we know and what we still need to learnSleep Medicine Reviews, 2002